Philae Pharmaceuticals is a dermatology spin-off company from the University Medical Center Groningen (UMCG). Philae is dedicated to the development of targeted therapies for severe and difficult-to-treat dermatological diseases. The initial disease Philae will focus on is Epidermolysis Bullosa (EB), a very rare but lethal disease for which currently no treatment or cure exists. Patients with EB are known as Butterfly Children because their skin is as vulnerable as the wings of a butterfly. Even the slightest contact or friction can easily tear or blister their skin.
More info: www.philae-pharma.com